BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Bone Biologics Release: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties

  Bone Biologics announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.

  December 20, 2017

   · 

  1 min read
• Policy

  3Shape Responds to Align Technology’s Sudden Termination of Invisalign Interoperability

  This is despite the fact that the interoperability has absolutely no legal link to the patent infringement allegations against 3Shape, which are completely unfounded and without merit.

  December 20, 2017

   · 

  2 min read
• Genetown

  Tarveda Therapeutics to Present at the 2018 Biotech Showcase

  Tarveda Therapeutics announced that Drew Fromkin, President and Chief Executive Officer, will present at the 10th Annual Biotech Showcase, occurring January 8-10, 2018 at the Hilton Union Square in San Francisco.

  December 20, 2017

   · 

  2 min read
• 

  Business

  Actelion Spin Out Joins Forces With Roche on Cancer Immunotherapy

  Idorsia today announced that it has entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds for a promising new approach in the field of cancer immunotherapy.

  December 20, 2017

   · 

  1 min read
• Business

  Dynasil Corporation of America Reports Fiscal Year 2017 Financial Results

  Dynasil Corporation of America today announced earnings attributable to common stockholders of $2.2M and $0.13 per common share for the fiscal year ended September 30, 2017 and the filing of its Annual Report on Form 10-K.

  December 20, 2017

   · 

  15 min read
• Drug Development

  Achillion Initiates Phase I First-in Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

  This initial phase 1 trial is a randomized, placebo-controlled, single-ascending dose study of ACH-5228 administered to healthy volunteers.

  December 20, 2017

   · 

  5 min read
• Pharm Country

  AzurRx BioPharma Announces Publication of U.S. Patent Application for AZX1101

  AZX1101 is intended to prevent the adverse effects of antibiotics, secondary to their action on the gastrointestinal flora and the selection of resistant bacteria strains.

  December 20, 2017

   · 

  3 min read
• Biotech Bay

  Avinger Receives CE Marking Approval for Next Generation Pantheris Image-Guided Atherectomy Device

  Avinger today announced CE Marking approval for its next generation Pantheris Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment of PAD.

  December 20, 2017

   · 

  3 min read
• Business

  Indi Molecular Appoints Stephen Worsley Senior VP Business Development

  Worsley is a seasoned life sciences executive who most recently served as Peregrine Pharma’s VP business development.

  December 20, 2017

   · 

  3 min read
• FDA

  Avillion Announces U.S. Approval of Pfizer’s BOSULIF (bosutinib) for the Treatment of Patients With Newly-Diagnosed Ph+ CML

  Avillion announces that the FDA today approved a supplemental sNDA for Pfizer’s BOSULIF (bosutinib).

  December 20, 2017

   · 

  5 min read